Amylyx Pharmaceuticals Inc. has announced plans to host an investor event at the Endocrine Society's annual meeting (ENDO 2025) to discuss post-bariatric hypoglycemia $(PBH)$ and avexitide, a potential first-in-class GLP-1 receptor antagonist. The event will take place on July 13, 2025, both in-person in San Francisco and virtually. The presentation will cover the current burden of PBH and provide background information on avexitide, which has received FDA breakthrough therapy designation. Additionally, the event will feature new exploratory analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide in PBH, with data focusing on composite rates of Level 2 and 3 hypoglycemic events, as well as pharmacokinetic and pharmacodynamic data demonstrating the continuous pharmacologic activity of the 90 mg once daily dose for 24 hours. The results of these studies will be presented during ENDO 2025. A live webcast of the presentation and Q&A will be available on Amylyx's website, with a replay accessible for 90 days following the event.